1184PA phase I/II safety study of tisotumab vedotin (HuMax®-TF-ADC) in patients with solid tumors. (18th September 2017) - Chenard-Poirier, M.; Hong, D.S.; Coleman, R.; de Bono, J.; Mau-Sorensen, M.; Collins, D.; Lisby, S.; Basse, L.; Lassen, U.